NASDAQ · Biotechnology

Verrica Pharmaceuticals Inc. (VRCA) Stock

$4.11 -1.67% NASDAQ: VRCA Healthcare

Valuation

MetricValue
Price$4.11
Market Cap$70.60M
P/E Ratio-2.52
P/B Ratio21.67
P/S Ratio2.48
EPS (TTM)$-1.68
52-Week High$9.82
52-Week Low$3.28
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-444.44%
ROA-86.58%
ROCE-207.23%
Gross Margin-33.33%
Operating Margin-33.33%
Net Margin-102.84%
Debt/Equity0.42
Current Ratio2.69

Annual Financials (USD)

Metric20212022202320242025
Revenue$12.0M$9.0M$5.0M$8.0M$36.0M
Operating Profit$-31.0M$-21.0M$-66.0M$-66.0M$-12.0M
Net Profit$-35.0M$-24.0M$-67.0M$-77.0M$-18.0M
EPS$-12.97$-7.17$-14.78$-14.78$-1.68
Op Margin-257.6%-235.8%-1283.3%-871.3%-33.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$80.0M$45.0M$82.0M$54.0M$47.0M
Total Liabilities$48.0M$5.0M$62.0M$64.0M$22.0M
Cash$16.0M$34.0M$70.0M$46.0M$30.0M
Borrowings$43.0M$2.0M$46.0M$46.0M$2.0M

Latest News

Verrica Pharmaceuticals Signs Distribution Deal With Medomie for Molluscum Treatment MT Newswires · Jul 21, 2026 Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel GlobeNewswire · Jul 21, 2026 Verrica Pharmaceuticals' Doses First US Patient in Phase 3 Trial Evaluating Ycanth to Treat Common Warts MT Newswires · Jun 22, 2026 Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts GlobeNewswire · Jun 22, 2026 Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-28.0M$-19.0M$-39.0M$-61.0M$-18.0M
Investing Cash Flow$-2.0M$54.0M$-1.0M$0$0
Financing Cash Flow$1.0M$0$0$0$0
Net Cash Flow$5.0M$19.0M$35.0M$-23.0M$-16.0M
Free Cash Flow$-28.0M$-19.0M$-39.0M$-61.0M$-18.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.07
EV / EBITDA-2.45
FCF Yield-17.74%
Quick Ratio1.33
Interest Coverage-7.54
Return 1Y-28.32%
Return 3Y-91.45%
Return 5Y-94.44%

Ownership

Insiders Held48.75%
Institutions Held27.87%
Institutions Float Held54.39%
Institutional HolderSharesReport Date
Caligan Partners, LP923,9102026-03-31
Affinity Asset Advisors, Llc707,3382026-03-31
Cannell Capital LLC685,1232026-03-31
Armistice Capital, LLC518,1812026-03-31
Velan Capital Investment Management LP471,5592026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. is led by CEO Jayson Rieger, employs 71 people, headquartered in US, publicly traded since 2018.

Verrica Pharmaceuticals Inc. (VRCA) stock trades at $4.11 with a market capitalization of $70.60M. The stock is valued at a price-to-earnings (P/E) ratio of -2.52, price-to-book of 21.67, price-to-sales of 2.48. Over the past 52 weeks the stock has ranged between $3.28 and $9.82, and currently trades 58.2% below its 52-week high.

On profitability, Verrica Pharmaceuticals Inc. generates a return on equity (ROE) of -444.44%, return on capital employed of -207.23%, an operating margin of -33.33%, a net profit margin of -102.84%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides